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Abstract: Despite significant improvement in therapy and management, heart failure remains a
worrisome disease state that is especially problematic in special populations. African Americans
suffer a disproportionately higher prevalence of heart failure when compared to other populations.
It has been recently demonstrated that vasodilator therapy using the combination of isosorbide
dinitrate (ISDN) and hydralazine (HYD) as an adjunct to background evidence-based therapy
appears to display the strongest signal of benefit in reducing mortality and morbidity in the African
American population. Through review of the retrospective and more recent prospective data, we
will focus on the benefit of ISDN-HYD as adjunctive therapy for use in African Americans with
systolic heart failure on concomitant appropriate evidence based therapy. This review also closely
examines some of the potential contributions to endothelial dysfunction in African Americans, and
the relationship of vascular homeostasis and nitric oxide. The role of oxidative stress in left
ventricular dysfunction will also be explored as a reduction of oxidative stress offers particular
promise in the management of heart failure. Although neurohormonal blockade has been responsible
for notable event reductions in patients with systolic heart failure, the addition of ISDN-HYD,
vasodilator therapy that enhances nitric oxide and reduces oxidative stress, further improves
quality of life and survival in African American patients with heart failure. These findings
strongly imply that nitric oxide enhancement and/or oxidative stress reduction may be important
new therapeutic directions in the management of heart failure.
Keywords: African American, heart failure, isosorbide dinitrate, hydralazine, American Heart
Failure Trial.
Despite significant advances in therapy, heart failure remains a disease state associated
with significant morbidity and mortality. At the age of 40, the estimated lifetime risk of
developing heart failure is as high as 40%, depending on the presence of uncontrolled
hypertension or other morbid cardiovascular conditions (American Heart Association
2006). In response to this disease burden, a number of clinical trial efforts have yielded
remarkable improvements in our understanding and treatment of systolic heart failure
(Yancy 2005). The deleterious effects of an activated neurohoromonal system in response
to left ventricular dysfunction have proven to be responsible for disease progression,
and treatment strategies to counteract these actions, eg, angiotensin converting enzyme-
inhibitors (ACE-I) and beta blockers, are now associated with notable reductions in
systolic heart failure hospitalizations and improvement in overall survival (Konstam
et al 1992; Bristow 2000; Hunt et al 2005). However, a fundamental question has been
raised—  do all patient populations benefit similarly from the advances noted in systolic
heart failure management?
African Americans continue to suffer a disproportionately higher prevalence of heart
failure when compared to Caucasians (Dries et al 2001). Systolic heart failure in African
Americans is less likely to correlate with a burden of coronary artery disease, but is more
likely to be associated with younger age and the presence of hypertension (Figure 1).
However, the exact mechanism and progression of hypertensive heart disease to systolicVascular Health and Risk Management 2006:2(4) 424
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dysfunction is not well understood. Effects of drug therapy in
African Americans with heart failure are also difficult to interpret.
A major obstacle prohibiting the evaluation of heart failure
therapy in African Americans is the inadequate representation
of African Americans in clinical trials. Data pertaining to drug
effect and outcome of heart failure in African Americans are
almost always based on post hoc analyses, which fail to have
sufficient power to detect meaningful endpoints within this
group. Therefore, the evidence for most systolic heart failure
drug therapy in African Americans is speculative at best. Even
so, treatment of heart failure in African Americans should follow
evidence based guidelines, as there is no evidence to date to
suggest that such a management plan is harmful for this group
(Hunt et al 2005; Yancy 2005).
Of all of the proven treatment regimens that have been
evaluated for evidence of efficacy in African Americans with
systolic heart failure, the vasodilators have emerged with the
strongest signal of benefit. Through post hoc analyses of the
earlier vasodilating trials, a “hypothesis-generating” concept
has led to a landmark trial, the African American Heart Failure
Trial [A-HeFT], which demonstrated the striking benefit of
ISDN-HYD as combination therapy, in African Americans
with systolic heart failure (Taylor et al 2004). It is the purpose
of this review article to develop the background, rationale
and scientific premise for these notable benefits of ISDN-
HYD as adjunctive therapy for heart failure.
Vasodilator therapy in heart failure
Prior to 1980, the effects of vasodilator therapy on heart failure
were not well understood. The Veterans Administration
Cooperation Study (V-HeFT I) was the first double blind
randomized controlled trial to examine this interaction (Cohn
et al 1986). The initial hypothesis evolved around the possibility
that peripheral vasoconstriction was responsible for
hemodynamic compromise and further progression of symptoms
in heart failure patients (Cohn et al 1986). The choice of ISDN-
HYD was based on the ability of this combination to reduce
preload (venodilation) and afterload (arterial dilation), similar
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Figure 1  Etiology of congestive heart failure in African Americans. Adapted from Cohn et al 1986; Cohn et al 1991; The SOLVD Investigators 1991; Packer et al 1996;
MERIT-HF Study Group 1999; The Beta-Blocker Evaluation of Survival Trial Investigators 2001.
Abbreviations: BEST, Beta-blocker Evaluation of Survival Trial; HF, heart failure; MERIT-HF, Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure;
SOLVD, Studies of Left  Ventricular Dysfunction; V-HeFT,  Vasodilator Heart Failure Trial; US Carvedilol, US Carvedilol Heart Failure Trial.Vascular Health and Risk Management 2006:2(4) 425
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to the effects seen with nitroprusside (Pierpont et al 1978). The V-
HeFT I study enrolled 642 men, of which 180 or 28% were African
American. All participants received either ISDN-HYD
combination (n = 186), prazosin (n = 183), or placebo (n = 273).
The average dose of ISDN-HYD combination was 136 mg and
270 mg respectively. Approximately 55% of the ISDN-HYD
group achieved the maximum dose (160 mg of ISDN and 300
mg of HYD). The mean period of follow-up was 2.3 years. At one
year, there was a 38% reduction in mortality for the patients
receiving ISDN-HYD, compared to placebo (12.1% vs 19.5%
respectively). At the end of the pre-specified time point of two
years, there was a 25% reduction in mortality (25.6% for the
ISDN-HYD group compared to 34.3% for the placebo group,
p < 0.028). The prazosin group had a mortality rate that was
similar to the placebo group, although there was greater blood
pressure reduction within the prazosin group when compared to
the ISDN-HYD group. At the end of the trial the overall
cumulative mortality reduction for the ISDN-HYD group was of
borderline statistical significance (p ~ 0.05). Despite the marginal
statistical signal, this trial demonstrated clinical significance
and was the first trial to demonstrate improved survival with
drug therapy for any heart failure population.
After the results of  V-HeFT I, the effects of the ISDN-HYD
combination therapy were further evaluated against an ACE-I,
enalapril, in V-HeFT II (Cohn et al 1991). Use of enalapril in
severe heart failure had previously demonstrated reduction in
mortality when compared to placebo in the Cooperative North
Scandinavian Enalapril Survival Study (The CONSENSUS
Trial Study Group 1987) in class IV heart failure. The V-HeFT
II trial enrolled 804 patients, and compared the use of ISDN-
HYD (maximum dose 160 mg and 300 mg repectively, divided
into four daily doses) to enalapril (maximum dose 20 mg daily).
At the pre-specified endpoint of two years, enalapril reduced
mortality 28% more than the ISDN-HYD therapy. Although
death from worsening heart failure did not differ between the
groups, there was a significant reduction in sudden cardiac
death with enalapril compared to the ISDN-HYD group. The
results from this study suggested that enalapril was superior to
ISDN-HYD therapy for improving survival in patients with
mild to moderate heart failure.
Racial differences in response to
vasodilator therapy: lessons from
V-HeFT I and II
As the studies of vasodilator therapies in heart failure
developed, there appeared to be a specific signal of
differential outcome between African Americans and
Caucasians. Retrospective analysis from the Studies of Left
Ventricular Dysfunction (SOLVD) Prevention and Treatment
trials demonstrated a significantly higher risk of death from
all causes in African Americans when compared with
Caucasians (Dries et al 1999). Further inspection of specific
drug therapies began to suggest differential effects between
races as well. A post hoc analysis of  V-HeFT I and II revealed
a striking difference in outcomes in the African Americans
who were administered ISDN-HYD therapy (Carson et al
1999). In V-HeFT I, there was a 47% reduction in mortality
for African Americans receiving ISDN-HYD combination
when compared with the African American patients in the
placebo group (9.7% vs 17.3% respectively, p = 0.04)
(Figure 2). When the use of ISDN-HYD was compared to
enalapril in African American patients from V-HeFT II, there
was no significant difference in mortality (12.9% vs 12.8%,
p = NS). However, the Caucasian patients had a 26%
reduction in mortality with the use of enalapril when
compared with the Caucasian patients receiving ISDN-HYD
therapy (11% vs 14.9% respectively, p = 0.02). Results of
this analysis suggested that African Americans patients with
heart failure had a heightened response to ISDN-HYD
therapy, similar to that seen with the use of ACE-inhibitors.
Further evaluation of the SOLVD study using case matched
Caucasians and African Americans demonstrated a similar
efficacy of enalapril on mortality but a differential effect
on hospitalizations (Exner et al 2001). Taken together, these
findings suggested that benefit from ACE-I therapy in
African Americans was evident and thus this therapy is
strongly recommended by current guidelines for all persons
with heart failure (Hunt et al 2005).
The reasons for these findings of differential response in
V-HeFT I and II were not well understood at the time. There
were several baseline differences in the African American
patients when compared with their Caucasian counterparts.
African American patients were younger, had less CAD, and
had a significantly higher incidence of hypertension (V-HeFT
II only). Interestingly, the Caucasian patients had higher
plasma norepinephrine when compared with the African
American patients, although there was no difference in renin
activity between groups. Patients with uncontrolled
hypertension or hypertension requiring more than diuretic
therapy were excluded from both V-HeFT I and II. This
exclusion undoubtedly eliminated a population in which
persistent hypertension may have been the nidus for systolic
impairment.Vascular Health and Risk Management 2006:2(4) 426
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The effects of nitric oxide (NO) and its relationship to
endothelial function in African Americans became a key area
of interest. Previous studies evaluating the response of innate
vasodilatory stimuli on forearm arterial resistance suggested
differential effects between African Americans and Caucasians
(Hinderliter et al 1996; Cardillo et al 1998; Kahn and Duffy
2002). Cardillo et al evaluated the racial differences in NO
mediated vasodilation on forearm arterial resistance in
relation to mental stress on normal patients. Mental stress, in
the form of serial seven subtractions, was used as a standard
measure to increase forearm blood flow. The increase in
forearm blood flow was easily demonstrated in the Caucasian
subjects but not in the African American subjects. Use of a
NO synthesis (NOS) inhibitor NG-monomethyl-L-arginine
(L-NMMA) infusion significantly reduced forearm blood flow
in Caucasian patients, where the forearm blood flow in African
American patients was unaffected. Results of this study
suggested impaired NO-related vasodilatory action of
endothelial and smooth muscle cell function in African
Americans- a finding that implicates endothelial dysfunction
in this group of patients.
More recent data evaluating the use of methacholine, a
parasympathetic agonist, in hypertensive patients also
demonstrated less vasodilatory response of forearm blood flow
in African American patients compared with Caucasians (Kahn
and Duffy 2002). These results echoed the previous findings
suggesting impaired endothelial vasomotor function in African
American patients. Even in normal individuals, there are
provocative data to suggest reduction in endothelium-derived
NO bioavailability in African Americans, when compared with
Caucasians (Kalinowski 2004). Moreover, these data are
accompanied by findings suggestive of increased oxidative
stress, ie, increased production of superoxide and peroxynitrite,
further increasing the likelihood of endothelial impairment in
African Americans.
Extrapolation of these findings may implicate the effects
of reduced NO bioavailability on myocyte function. Nitric
oxide is generated by NOS, neuronal NOS (nNOS or NOS1),
inducible NOS (iNOS or NOS2), and endothelial NOS (eNOS
or NOS3), which convert L-arginine to L-citrulline in the
presence of molecular oxygen, nicotinamide-adeninine
dinucleotide phosphate (NADPH), calmodulin, and other
cofactors (Prabhu 2004, p 1155). Dysfunctional endothelium
hinders the production and bioavailability of NO, which
increases the production of reactive oxygen species and
oxidative stress. Reduced concentrations of  NO cosubstrates,
such as L-arginine, promote inactivation of eNOS and 1
electron reduction of O2 to O2-, also known as superoxide.
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Figure 2  V-HeFT 1. survival benefit in subgroup analysis.  Adapted from Carson et al (1999).Vascular Health and Risk Management 2006:2(4) 427
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Increased production of O2-, further increases oxidative stress
by reacting with available NO to form peroxynitrite [ONOO–]
(Hare 2004; Malinski 2005). Production of peroxynitrite is
associated with proapoptotic effects, possibly contributing
to increased ventricular remodeling and impairment of
systolic function. Nitric oxide is also responsible for
antihypertrophic effects, primarily mediated by cGMP-
dependent protein kinases (Wollert and Drexler 2002).
Overexpression of NO synthase 3 (NOS3) has been
demonstrated to reduce myocyte hypertrophy after myocardial
infarction in animal models, suggesting greater antihypertrophic
effects with increased production of physiological levels of
NO (Janssens et al 2004). Total eNOS protein appears to be
increased in African Americans, but there is lack of
biologically active NO production (Malinski 2005). It is
reasonable to presume that reduced NO bioavailability may
alter myocyte function and increase cardiac hypertrophy.
However, these concepts are controversial, as higher or
“supernormal” levels of  NO (perhaps related to iNOS
activation), appear to induce caspase activation, DNA
fragmentation, and cell death (Wollert and Drexler 2002,
p 320). This is a thought-provoking hypothesis, as the majority
of evidence suggests that a relative NO deficiency is present
in African Americans. Utilization of ISDN-HYD therapy may
indeed replete NO in this group, possibly altering steady
state NO balance without causing the deleterious cellular
effects (Figure 3).
These preliminary data suggest impairment in NO
production as well as endothelial dysfunction in African
Americans as a mechanism for several vascular complications,
including endothelial damage, hypertension-related
complications, concentric left ventricular hypertrophy and
possibly the progression of left ventricular dysfunction due
to hypertension in the absence of ischemic heart disease.
Figure 3  Consequences of nitric oxide and super oxide balance disruption in heart failure patients. Adapted from Hare (2004).Vascular Health and Risk Management 2006:2(4) 428
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This is a hypothesis that will require careful testing before
these mechanisms can be deemed definitive.
Effects of hydralazine on oxidative
stress and nitrate tolerance
Although HYD is a potent vasodilator, progressive
investigations suggest that reduction in oxidative stress and
nitrate tolerance are as likely associated with the clinical benefit
seen in patients with heart failure (Unger et al 1993; Gogia et al
1995; Diaber et al 2005). HYD has been associated with
reduction of free radical scavengers in vitro, primarily from
dose-dependent reduction of superoxide and peroxynitrite
signaling (Daiber et al 2005). Daiber and colleagues also
evaluated the effects of HYD on nitroglycerin-induced
superoxide and peroxynitrite production from cardiac
mitochondria in vitro. In a dose-dependent fashion, HYD
suppressed the production of the free radicals, suggesting that
HYD attenuated oxidative stress in a nitrate rich environment.
Multiple studies have evaluated HYD effects on nitrate
tolerance in the setting of heart failure (Cohn et al 1986;
Cohn et al 1991; Gogia et al 1995; Taylor et al 2004; Daiber
et al 2005; Elkayam and Bitar 2005). Gogia and colleagues
evaluated the hemodynamic effects of intravenous
nitroglycerin with HYD in patients with heart failure. A
total of 28 patients (2 groups of 14) received a 24-hour
infusion of nitroglycerin either with or without oral HYD
administration. Use of  HYD was associated with sustained
reductions in blood pressure, pulmonary artery pressure,
and mean pulmonary artery wedge pressure, whereas these
effects quickly weaned in the group receiving only
nitroglycerin (Gogia et al 1995). This study and others suggest
that HYD is associated with sustained effect of nitrate
administration by reducing overall tolerance of therapy.
Based on this background of basic science, provocative
mechanistic data and clinical observation, the African
American Heart Failure Trial (A-HeFT) was initiated to
evaluate the use of ISDN-HYD in African American patients
with advanced systolic heart failure already treated with
evidence-based neurohormonal blockade.
The A-HeFT experience
The A-HeFT study randomized 1050 African American
patients with moderate to severe systolic heart failure (NYHA
III and IV) to fixed-dose ISDN-HYD therapy or placebo
(Taylor 2003, 2005; Taylor et al 2004). A fixed-dose tablet of
HYD 37.5 mg and ISDN 20 mg was administered 3 times
daily (total daily dose HYD 112.5 mg and ISDN 60 mg). The
dose was titrated to 2 tablets 3 times daily, for a total dose of
HYD 225 mg and ISDN 120 mg. The maximum doses and
frequency of  ISDN-HYD were lower in the A-HeFT trial when
compared with V-HeFT I and II (HYD 300 mg, ISDN 160 mg).
The majority of all patients within the trial were taking
diuretics, ACE-I/angiotensin receptor blockers, beta-blockers,
and digoxin. Approximately 38%–40% of the patients were
receiving aldosterone antagonists at the time of enrollment.
The average ejection fraction for both groups was 24%. At
the end of the trial, approximately 68% of the patients
achieved maximal therapy in the ISDN-HYD group. The
primary endpoint was a composite score composed of
weighted values for death from any cause, first hospitalization
for heart failure, and quality of life at 6 months. The
Minnesota Living with Heart Failure questionnaire was used
to assess quality of life. This was the first heart failure trial
that utilized this composite endpoint. The composite system
was designed to consider all mortality/morbidity events that
contribute to heart failure outcome (Taylor 2003). Secondary
outcome included the separate components of the composite
system, death from cardiovascular causes, the total number
of hospitalizations for any reason, the total number of days
of hospitalization, the overall quality of life throughout the
trial, the number of unscheduled emergency room and clinic
visits, the change in B-type natriuretic peptide level at six
months, new need for cardiac transplantation, and change in
myocardial remodeling at six months (Taylor et al 2004,
p 2050).
The study was terminated early as there was a significantly
lower mortality in the ISDN-HYD group (6.2% vs 10.2% in
the placebo group, p = 0.02). The mean duration of follow-up
was 10 months. Overall, there was a 43% reduction in
mortality with the use of ISDN-HYD therapy (10.2% in the
placebo group vs 6.2% in the ISDN-HYD group; Hazard Ratio
0.57, p = 0.01). The primary endpoint composite score was
also significantly improved in the ISDN-HYD group. Based
on the prespecified endpoints, quality of life was improved
as well. There was a 33% reduction in the rate of first
hospitalization in the ISDN-HYD group compared with the
placebo group, as well as a reduced rate of severe heart failure
exacerbations in the treatment group (Figure 4).
Although there was a dramatic reduction in mortality for
the patients receiving ISDN-HYD therapy in the A-HeFT study,
the Kaplan-Meier survival curves did not separate until
approximately 180 days after randomization. The reason for
this occurrence is not yet understood. The fact that both groups
of patients were receiving optimal neurohormonal antagonismVascular Health and Risk Management 2006:2(4) 429
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and diuretic therapy may explain why the survival curves did
not separate earlier. However this may also suggest a survival
advantage from improvement of pump function due to a reverse
remodeling effect. Further analyses of the trial data are ongoing
to confirm this hypothesis. Nevertheless, these findings of the
A-HeFT study firmly establish the use of ISDN-HYD
combination in addition to evidence based neurohormonal
blockade in African Americans with moderately severe to
severe heart failure. The data are less clear for the use of this
combination vasodilator therapy in patients with mild heart
failure (NYHA I or II), as there was virtually no enrollment of
these populations in the A-HeFT study.
Genetic implications and
“race-based therapeutics”
Although self-reported race or ethnicity is currently the basis
for patient selection related to this therapeutic intervention,
it is clear that race is neither a scientific or physiological
grouping and merely represents a placeholder for some other
more objective marker of disease and/or response to therapy.
It is plausible that genetic variations or polymorphisms may
offer better explanations for differential effects of some
therapies (Yancy 2005). Genetic variants of the alpha2c-
adrengergic receptor (α2cDel322-325) and β1-adrenergic
receptor (β1Arg389) have been associated with increased risk
for heart failure (Small et al 2002). The alpha2c-adrengergic
receptor is partially responsible for feedback regulation of
norepinephrine release in the sympathetic nerves. The
presence of the genetic variant α2cDel322-325 of this receptor
is associated with decreased regulatory function and
increased presynaptic release of norepinephrine from the
sympathetic ganglion (Hein et al 1999). The β1-adrenergic
receptor variant (β1Arg389) of the cardiomyocyte has been
associated with increased coupling to the stimulatory G
protein, increasing intracellular cyclic AMP. This over-
stimulation of the cardiac myocytes produce increased
chronotropy and inotropy, placing the heart at greater risk
for failure (Small et al 2002).
Small and colleagues evaluated a small cohort of African
American and Caucasian patients with and without heart
failure to assess whether these genetic variants were related
to increased frequency of heart failure. Although all patients
homozygous for the α2cDel322-325 allele were at greater
risk for developing heart failure, the African American patients
were more commonly homozygous for this allele. African
Americans also had a higher association with the combination
homozygous alleles of α2cDel322-325 and β1Arg389 receptor
variant, which significantly increased their risk for heart
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failure, when compared with the Caucasian patients of the
cohort (odds ratio 10.11, 95% CI, 2.11–48.53, p = 0.004).
Recent investigations from the genetics substudy of
A-HeFT (GRAHF study) regarding the NOS3 gene have also
yielded some intriguing findings, in relation to African
Americans with heart failure. A genetic variant of the NOS3
gene (Asp298 variant) has been previously detected and
correlated with worse outcome in Caucasian patients with
systolic dysfunction (McNamara et al 2003). The Asp
298
variant of the NOS3 gene has a shorter-half-life in vitro, which
is thought to be responsible for reduce nitric oxide production
(Tesauro et al 2000). The Genetic Risk Assessment in Heart
Failure (GRAHF) study evaluated the NOS3 polymorphisms
within the African American cohort, and detected the Asp
298
variant in approximately 80% of the patients (McNamara
et al 2005). This frequency was significantly higher than the
56% frequency detected in a previous Caucasian cohort
(McNamara et al 2003). These studies and others provide
new insight into the genetic variants and outcome of the
African American population with systolic heart failure.
Further evaluation of “gene-tailored” therapies is now required
to assess whether this mode of treatment will alter the overall
outcome and prognosis in this group.
Conclusion
Growing evidence now suggests that there are definite
differences in the experience of heart failure as it affects
African Americans. It is evident that the presumed etiology
of left ventricular dysfunction, the natural history of the
disease and responsiveness to standard therapeutic
interventions may vary. Prior to the A-HeFT study, the data
regarding the benefit of ISDN-HYD therapy in African
Americans lacked statistical power to demonstrate significant
benefit in any group. However, after almost 20 years of effort,
investigators have demonstrated that utilization of ISDN-
HYD in addition to standard medical therapy for heart failure
tested specifically for African Americans with heart failure is
effective and appropriate. Although the results of A-HeFT
are of interest, emphasis of other evidence based strategies
must not go unnoticed, as there are no data to support
discontinuance or avoidance of other appropriate therapies
for African American patients with heart failure. As well, it is
presumed that these findings are not race-specific but rather
that within the African American cohort, there are a sufficient
number of responders to uncover a strong signal of efficacy.
The work that now needs to be done is that which will uncover
the specific epidemiological, clinical, biological and genetic
signals specific for this robust response to ISDN-HYD.
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